TY - JOUR ID - 60678 TI - Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Tariq, Ayesha AU - Aziz, Muhammad Tahir AU - Mehmood, Yasir AU - Asghar, Shehroz Ali AU - Khurshid, Azhar AD - University of Central Punjab, Lahore, Pakistan. AD - Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. AD - Department of Pharmacy, Government College University Faisalabad, Lahore, Pakistan. AD - Basic Health Unit Mureedky, Lahore, Pakistan. Y1 - 2018 PY - 2018 VL - 19 IS - 5 SP - 1181 EP - 1184 KW - Keywords: CHOP KW - RCHOP KW - clinical response evaluation KW - DLBCL DO - 10.22034/APJCP.2018.19.5.1181 N2 - Purpose: The purpose of this study was to address the question of “superiority of R-CHOP versus CHOP”, withaddition of Rituximab to CHOP, regarding survival of patients suffering from DLBCL. Patients and methods: A cohortretrospective design was used to conduct this study in a tertiary care hospital. A total of 100 patients (50 in each group)were randomly selected. The primary and secondary end points were EFS, OS, PFS and DFS. Kaplan Meier survivalcurve analysis (log rank, Breslow and Tarone ware tests) was employed to compare probability of survival for the twogroups (CHOP/ R-CHOP). Results: The mean primary and secondary clinical indicators were estimated for each group(EFS, 1.7; 3.09 with a p value P=0.02), (OS, 0.60; 0.43 with a p value P=0.40), (PFS, 1.73; 3.57 with a p value P=0.002), (DFS, 0.02; 0.48 with a p value of P=0.00). Conclusion:The results for differences in clinical response were statistically significant in favor of the R-CHOP group. UR - https://journal.waocp.org/article_60678.html L1 - https://journal.waocp.org/article_60678_cbc6144ea30ca946dac773031ce96323.pdf ER -